FINWIRES · TerminalLIVE
FINWIRES

BASE Extends Confidentiality Agreement With Shareholder Hiroyuki Maki

By

BASE (TYO:4477) extended the effective period of its confidentiality agreement with shareholder Hiroyuki Maki by an additional three months as the company continues friendly engagement discussions aimed at enhancing corporate value and shareholder interests, according to a Tuesday filing on the Tokyo Stock Exchange.

The extension brings the agreement period to one year from its original execution date in August 2025. No other terms of the agreement were changed.

BASE said it will continue discussions with Maki and pursue initiatives aimed at strengthening corporate value and the common interests of shareholders. The company first entered into the confidentiality agreement in August 2025 alongside the abolition of its anti-takeover policy framework.

Related Articles

Asia

KDDI's Full-Year Profit Rises 7.9%

KDDI's (TYO:9433) profit attributable to owners of the parent climbed 7.9% to 707.1 billion yen for the fiscal year ended March 31, from 655.4 billion yen a year earlier.The telecommunication company's earnings per share increased to 183.55 yen from 161.81 yen a year ago, according to a Tokyo bourse filing on Tuesday.Operating revenue rose 4.1% to 6.072 trillion yen from 5.836 trillion yen in the prior year.It declared a final dividend of 40 yen per share, payable from June 29.For the fiscal year ending March 31, 2027, the company expects adjusted attributable profit of 731 billion yen, adjusted basic EPS of 196.29 yen, and operating revenue of 6.41 trillion yen.KDDI plans to pay interim and year-end dividends of 42 yen per share each for the year, higher than the amount paid in the year-ago period.

$TYO:9433
Asia

China Stocks Fall Amid Anticipation of Trump-Xi Summit; Rare Earths Slide

Chinese stocks declined Tuesday as investors await with bated breath the outcome of the talks between Presidents Donald Trump and Xi Jinping.The Shanghai Composite Index, the main gauge of Chinese stocks, lost 0.3% or 10.53 points to reach 4,214.49. The Shenzhen Component Index fell 0.5% or by 74.38 points to 15,824.92.China and the U.S. should take a long-term view to ensure continuing trade and economic relations between the two countries, an editorial by the Communist Party's People's Daily newspaper said."Economic and trade relations continue to serve as the 'ballast' and 'propeller' of China-US relations," the editorial said.Meanwhile, the CSI Rare Earth Industry Index slid 3% during the closing bell, leading onshore declines. China Northern Rare Earth (Group) High-Tech (SHA:600111) plunged 6% while China Rare Earth Resources and Technology (SHE:000831) closed 4% lower.Ningbo Hicon Industry Technology (SHE:001237) priced its initial public offering at 53.26 yuan per sahre, while Jiadeli Electronics Material (SHA:603435) priced its offering at 15.76 yuan apiece.

$^SSEC$^SZSE$SHA:600111$SHA:603435$SHE:000831$SHE:001237
Asia

Hong Kong Stocks End Lower as U.S.-Iran Talks Remain Stalled; Hengrui Pharma Jumps

Hong Kong stocks ended slightly lower on Tuesday as fading expectations for progress in U.S.-Iran negotiations and caution ahead of U.S. inflation data weighed on sentiment.The Hang Seng Index shed 0.2%, or 58.93 points, to close at 26,347.91, while the Hang Seng China Enterprises Index barely moved in negative territory to finish at 8,882.37.U.S. President Donald Trump said on Monday that a ceasefire with Iran was "on life support" after Tehran's response to a U.S. proposal highlighted divisions between the two sides.Tehran has called for compensation for war-related damage, an end to the U.S. naval blockade, assurances against further attacks, and the resumption of Iranian oil exports.Markets are also closely watching Trump's visit to China, which begins on Wednesday.In corporate news, Hengrui Pharmaceuticals (HKG:1276, SHA:600276) advanced nearly 5% in Hong Kong after signing a drug development deal with Bristol Myers Squibb worth up to $15.2 billion.

$^HSI$HKG:1276$SHA:600276